EP Patent

EP2648520A1 — Dexmedetomidine premix formulation

Assigned to Hospira Inc · Expires 2013-10-16 · 13y expired

What this patent protects

Pharmaceutical compositions comprise dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The …

USPTO Abstract

Pharmaceutical compositions comprise dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used in perioperative care of a patient or for sedation.

Drugs covered by this patent

Patent Metadata

Patent number
EP2648520A1
Jurisdiction
EP
Classification
Expires
2013-10-16
Drug substance claim
No
Drug product claim
No
Assignee
Hospira Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.